Literature DB >> 6117570

Hepatic and renal metabolism of somatostatin-like immunoreactivity. Simultaneous assessment in the dog.

K S Polonsky, J B Jaspan, M Berelowitz, D S Emmanouel, J Dhorajiwala.   

Abstract

The hepatic and renal metabolism of somatostatin-like immunoreactivity (SLI) was assessed simultaneously in an in vivo dog model. The hepatic extraction of this peptide was 29.4 +/- 2.3% and was similar for endogenous and infused exogenous SLI. The renal extraction was 62.3 +/- 5%. The renal clearance of SLI was significantly greater than that of inulin indicating that the peptide is handled by peritubular uptake from postglomerular blood in addition to glomerular filtration. In both organs SLI extraction was not saturable even at arterial concentrations in excess of 100 times physiological range. The overall metabolic clearance rate of SLI was 19.7 +/- 1.6 ml/kg per minute of which 32.7 +/- 4.6% was contributed by hepatic and 37 +/- 4.9% by renal uptake mechanisms. The plasma half disappearance time of exogenously infused SLI was 1.9 +/- 0.3 min. The studies indicate that in the dog, the liver and kidney are both major sites of SLI metabolism, together accounting for 70.0 +/- 8.7% of the metabolic clearance of the peptide.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6117570      PMCID: PMC370908          DOI: 10.1172/jci110359

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  36 in total

1.  Studies on the inhibition of insulin release, glycogenolysis and gluconeogenesis by somatostatin in the rat islets of langerhans and isolated hepatocytes.

Authors:  J R Oliver; S R Wagle
Journal:  Biochem Biophys Res Commun       Date:  1975-02-03       Impact factor: 3.575

2.  Glucagon antibodies and an immunoassay for glucagon.

Authors:  R H UNGER; A M EISENTRAUT; M S McCALL; L L MADISON
Journal:  J Clin Invest       Date:  1961-07       Impact factor: 14.808

3.  Isolation and structure of somatostatin from porcine hypothalami.

Authors:  A V Schally; A Dupont; A Arimura; T W Redding; N Nishi; G L Linthicum; D H Schlesinger
Journal:  Biochemistry       Date:  1976-02-10       Impact factor: 3.162

4.  Somatostatin: hypothalamic inhibitor of the endocrine pancreas.

Authors:  D J Koerker; W Ruch; E Chideckel; J Palmer; C J Goodner; J Ensinck; C C Gale
Journal:  Science       Date:  1974-04-26       Impact factor: 47.728

5.  Somatostatin-like immunoreactivity in the retina.

Authors:  T Yamada; D Marshak; S Basinger; J Walsh; J Morley; W Stell
Journal:  Proc Natl Acad Sci U S A       Date:  1980-03       Impact factor: 11.205

6.  Clearance of immunoreactive somatostatin by perfused rat liver.

Authors:  H Sacks; L C Terry
Journal:  J Clin Invest       Date:  1981-02       Impact factor: 14.808

7.  Hepatic extraction of plasma immunoreactive glucagon components. Predilection for 3500-dalton glucagon metabolism by the liver.

Authors:  J B Jaspan; K S Polonsky; S Röjdmark; T Ishida; J B Field; A H Rubenstein
Journal:  Diabetes       Date:  1981-09       Impact factor: 9.461

8.  Factors influencing the handling of insulin by the isolated rat kidney.

Authors:  R Rabkin; A E Kitabchi
Journal:  J Clin Invest       Date:  1978-07       Impact factor: 14.808

9.  Prevention of human diabetic ketoacidosis by somatostatin. Evidence for an essential role of glucagon.

Authors:  J E Gerich; M Lorenzi; D M Bier; V Schneider; E Tsalikian; J H Karam; P H Forsham
Journal:  N Engl J Med       Date:  1975-05-08       Impact factor: 91.245

10.  Peripheral plasma somatostatin-like immunoreactive responses to insulin hypoglycemia and a mixed meal in healthy subjects and in noninsulin-dependent maturity-onset diabetics.

Authors:  A I Vinik; N S Levitt; B L Pimstone; L Wagner
Journal:  J Clin Endocrinol Metab       Date:  1981-02       Impact factor: 5.958

View more
  7 in total

Review 1.  Endogenous somatostatin and the gut.

Authors:  M R Lucey
Journal:  Gut       Date:  1986-04       Impact factor: 23.059

2.  Pharmacokinetic profile of the somatostatin analogue lanreotide in individuals with chronic hepatic insufficiency.

Authors:  Brian Tomlinson; Neil G Thomas; Irene W Lan; Manuel Barbanoj; Rosa M Antonijoan; Eva Drazna; Joaquim Ramis; Rosendo Obach; Concepción Peraire
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

Review 3.  Biochemistry and physiology of gastrointestinal somatostatin.

Authors:  M R Lucey; T Yamada
Journal:  Dig Dis Sci       Date:  1989-03       Impact factor: 3.199

4.  C-peptide and insulin secretion. Relationship between peripheral concentrations of C-peptide and insulin and their secretion rates in the dog.

Authors:  K S Polonsky; W Pugh; J B Jaspan; D M Cohen; T Karrison; H S Tager; A H Rubenstein
Journal:  J Clin Invest       Date:  1984-11       Impact factor: 14.808

5.  Human insulin B24 (Phe----Ser). Secretion and metabolic clearance of the abnormal insulin in man and in a dog model.

Authors:  S E Shoelson; K S Polonsky; A Zeidler; A H Rubenstein; H S Tager
Journal:  J Clin Invest       Date:  1984-05       Impact factor: 14.808

6.  Contribution of the pancreas to circulating somatostatin-like immunoreactivity in the normal dog.

Authors:  G J Taborsky; J W Ensinck
Journal:  J Clin Invest       Date:  1984-01       Impact factor: 14.808

7.  Metabolism of C-peptide in the dog. In vivo demonstration of the absence of hepatic extraction.

Authors:  K Polonsky; J Jaspan; W Pugh; D Cohen; M Schneider; T Schwartz; A R Moossa; H Tager; A H Rubenstein
Journal:  J Clin Invest       Date:  1983-09       Impact factor: 14.808

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.